- It is a systematic approach to pharmaceutical development and Medical software manufacturing.
- Sufficient details of development and manufacturing information to be in regulatory submissions.
- It does not equal Design Space (DS) and the design of experimental (DOEs)
- The regulatory decisions will be based on scientific and QRM principles using the Software for medicine process development.
- It does not need to be expensive, and it can also reduce the manufacturing and regulatory cost.
- It is crucial for products included in generics and producing new pharmaceutical products.
- Analytical testing is vital, and it plays a significant role in the development and implementation of QbD.